Edition:
India

Jubilant Life Sciences Ltd (JULS.NS)

JULS.NS on National Stock Exchange of India

847.85INR
11:40am IST
Change (% chg)

Rs-13.35 (-1.55%)
Prev Close
Rs861.20
Open
Rs889.70
Day's High
Rs909.00
Day's Low
Rs840.40
Volume
1,094,901
Avg. Vol
571,362
52-wk High
Rs909.00
52-wk Low
Rs234.35

Latest Key Developments (Source: Significant Developments)

Jubilant Life Sciences Launches Remdesivir For Injection Under Brand Name 'JUBI-R'
Monday, 3 Aug 2020 

Aug 3 (Reuters) - Jubilant Life Sciences Ltd ::JUBILANT LIFE SCIENCES LTD SAYS UNIT HAS LAUNCHED REMDESIVIR FOR INJECTION UNDER BRAND NAME 'JUBI-R'.JUBILANT LIFE SCIENCES LTD SAYS LAUNCHED 'JUBI-R' IN INDIAN MARKET AT 4,700 RUPEES PER VIAL OF 100 MG.CO TO MAKE DRUG AVAILABLE TO OVER 1,000 HOSPITALS PROVIDING COVID-19 TREATMENT IN INDIA THROUGH DISTRIBUTION NETWORK.  Full Article

Jubilant Life Sciences Says Approved Demerger Of The Life Science Ingredients Business
Friday, 25 Oct 2019 

Oct 25 (Reuters) - Jubilant Life Sciences Ltd ::JUBILANT LIFE SCIENCES LTD SAYS HAS APPROVED DEMERGER OF THE LIFE SCIENCE INGREDIENTS BUSINESS.  Full Article

Jubilant Life Sciences Approves Appointment Of Alok Vaish As CFO
Friday, 25 Oct 2019 

Oct 25 (Reuters) - Jubilant Life Sciences Ltd ::JUBILANT LIFE SCIENCES LTD SAYS APPROVED APPOINTMENT OF ALOK VAISH AS CHIEF FINANCIAL OFFICER.  Full Article

India's Jubilant Life Sciences Dec Qtr Consol Net Profit Rises
Friday, 1 Feb 2019 

Feb 1 (Reuters) - Jubilant Life Sciences Ltd ::DEC QUARTER CONSOL NET PROFIT 2.67 BILLION RUPEES VERSUS PROFIT OF 2.13 BILLION RUPEES LAST YEAR.DEC QUARTER CONSOL INCOME FROM OPERATIONS 23.53 BILLION RUPEES VERSUS 20.41 BILLION RUPEES LAST YEAR.  Full Article

India's Jubilant Life Sciences Sept-Quarter Profit Rises
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Jubilant Life Sciences Ltd ::SEPT QUARTER CONSOL NET PROFIT 2.10 BILLION RUPEES VERSUS PROFIT OF 1.28 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR SEPT QUARTER CONSOL NET PROFIT WAS 2.16 BILLION RUPEES.SEPT QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 22.69 BILLION RUPEES VERSUS 16.42 BILLION RUPEES LAST YEAR.JUBILANT LIFE SCIENCES LTD - EXPECTS BETTER PERFORMANCE IN H2FY19 AS COMPARED TO H1FY19 IN BOTH PHARMACEUTICALS AND LSI SEGMENTS.  Full Article

BRIEF-Jubilant Life Sciences Issues Commercial Papers Of 500 Mln Rupees

* ISSUANCE OF COMMERCIAL PAPERS OF 500 MILLION RUPEES Source text for Eikon: Further company coverage: